ARS Pharmaceuticals is no longer the founder-run launch story that spent its way into the epinephrine aisle. In July the board terminated co-founder Richard Lowenthal without cause and handed the company to Donn Casale, a commercial operator who had been president for barely a month. Casale's first earnings call abandoned the broad consumer campaign that defined the first year of neffy, the needle-free epinephrine nasal spray, and recast the equity as a provider-conversion problem in a prevention market that still sits at only 5% domestic epinephrine share. The debate is whether office-by-office selling can keep growing share after the advertising budget is cut.
The field data is the only reason the reset is even plausible. Where the sales team calls, share is 8%. Where it does not, share is about 1%. That gap is the entire commercial case. Second-quarter domestic product sales of $26.2 million doubled the year-ago print, and more than sixteen thousand unique prescribers wrote neffy in the period. The cost of that print was selling expense of $77.6 million, including a consumer media campaign the new plan is now discarding. Cash and short-term investments fell to $143.8 million from the year-end balance as first-half operations consumed more than $100 million.
The second half is the first clean test of the new operating system. Management guided cash-based selling and research spend of $100 million to $110 million. That is a cut of more than 40% from the first-half run rate. The company still claims a path to cash-flow breakeven by the end of 2027. Book equity is only $12.5 million against term loans near $97 million. An ALK financing liability of $75 million sits on top of that stack. The question the next two quarters resolve is whether targeted share keeps compounding after the consumer ads stop, or whether the launch was buying awareness that the cash account can no longer afford.